title: Persistent pulmonary hypertension of the newborn.
abstract: Persistent pulmonary hypertension of the newborn (PPHN) is a severe pulmonary disorder which occurs at a rate of one in every 500 live births. About 10-50% of the victims will die of the problem and 7-20% of the survivors develop long-term impairments such as hearing deficit, chronic lung disease, and intracranial bleed. Most adult survivors show evidence of augmented pulmonary vasoreactivity, suggesting a phenotypical change. Several animal models have been used to study the pathophysiology and help to develop new therapeutic modality for PPHN. The etiology of PPHN can be classified into three groups: (1) abnormally constricted pulmonary vasculature as a result of parenchymal diseases; (2) hypoplastic pulmonary vasculature; and (3) normal parenchyma with remodeled pulmonary vasculature. Impaired vasorelaxation of pulmonary artery and reduced blood vessel density in lungs are two characteristic findings in PPHN. Medical treatment includes sedation, oxygen, mechanical ventilation, vasorelaxants (inhaled nitric oxide, inhaled or intravenous prostacyclin, intravenous prostaglandin E1, magnesium sulfate), and inotropic agents. Phosphodiesterase inhibitors have recently been studied as another therapeutic agent for PPHN. Endothelin-1 (ET-1) inhibitors have been studied in animals and a case of premature infant with PPHN successfully treated with an ET-I inhibitor has been reported in the literature. Surfactants have been reported as an adjunct treatment for PPHN as a complication of meconium aspiration syndrome. Even with the introduction of several new therapeutic modalities there has been no significant change in survival rate. Extracorporeal membrane oxygenator is used when medical treatment fails and the patient is considered to have a recoverable cause of PPHN.
authors.affiliation: Division of Neonatology, Department of Pediatrics, Medical College of Wisconsin, Wauwatosa, WI 53226, USA. rteng@mcw.edu
authors.forename: Ru-Jeng
authors.initials: RJ
authors.lastname: Teng
authors.forename: Tzong-Jin
authors.initials: TJ
authors.lastname: Wu
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D015199:Extracorporeal Membrane Oxygenation; D005317:Fetal Growth Retardation / Q000503:physiopathology; D006801:Humans; D052250:Nitric Oxide Synthase Type III / Q000502:physiology; D010547:Persistent Fetal Circulation Syndrome / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D012121:Respiration, Artificial; D012307:Risk Factors
chemical_list: D052250:Nitric Oxide Synthase Type III
references.citation: Semin Perinatol. 1997 Oct;21(5):393-408
references.pmid: 9352612
references.citation: Acta Paediatr. 2005 Jul;94(7):896-902
references.pmid: 16188812
references.citation: Pediatrics. 1995 Sep;96(3 Pt 1):472-4
references.pmid: 7651780
references.citation: Pediatrics. 1988 May;81(5):650-6
references.pmid: 2451802
references.citation: Am J Physiol Lung Cell Mol Physiol. 2003 Aug;285(2):L305-12
references.pmid: 12665466
references.citation: N Engl J Med. 2006 Feb 9;354(6):579-87
references.pmid: 16467545
references.citation: Pediatrics. 2006 Apr;117(4):1077-83
references.pmid: 16585301
references.citation: J Pediatr. 2008 Dec;153(6):790-4
references.pmid: 18675433
references.citation: Am J Respir Crit Care Med. 2003 Aug 15;168(4):456-63
references.pmid: 12714351
references.citation: Am J Physiol Lung Cell Mol Physiol. 2008 Dec;295(6):L979-87
references.pmid: 18790993
references.citation: Pediatrics. 1992 Dec;90(6):899-904
references.pmid: 1437431
references.citation: J Pediatr. 1981 Jun;98(6):962-7
references.pmid: 7229803
references.citation: Am J Physiol. 1996 Jul;271(1 Pt 2):H8-14
references.pmid: 8760151
references.citation: Circulation. 1995 Aug 1;92(3):606-13
references.pmid: 7634475
references.citation: N Engl J Med. 2001 Jun 14;344(24):1832-8
references.pmid: 11407344
references.citation: J Pediatr. 2009 Dec;155(6):841-847.e1
references.pmid: 19836028
references.citation: Am J Physiol Lung Cell Mol Physiol. 2011 Sep;301(3):L334-45
references.pmid: 21622842
references.citation: Biol Neonate. 2000 Oct;78(3):220-9
references.pmid: 11044772
references.citation: Pediatrics. 2000 Jan;105(1 Pt 1):14-20
references.pmid: 10617698
references.citation: J Pediatr. 2011 Feb;158(2 Suppl):e19-24
references.pmid: 21238701
references.citation: Crit Care. 2001;5(3):158-66
references.pmid: 11353933
references.citation: Pediatr Pulmonol. 2003 Dec;36(6):529-35
references.pmid: 14618646
references.citation: Pediatrics. 2004 Mar;113(3 Pt 1):559-64
references.pmid: 14993550
references.citation: J Pediatr. 2011 Mar;158(3):383-389.e2
references.pmid: 20947097
references.citation: Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6448-53
references.pmid: 8692835
references.citation: Am J Physiol. 1997 Feb;272(2 Pt 2):H669-78
references.pmid: 9124423
references.citation: Nitric Oxide. 2003 Dec;9(4):201-10
references.pmid: 14996427
references.citation: Pediatrics. 2001 Mar;107(3):519-23
references.pmid: 11230592
references.citation: Antioxid Redox Signal. 2003 Dec;5(6):759-69
references.pmid: 14588149
references.citation: J Pediatr. 2000 May;136(5):611-7
references.pmid: 10802492
references.citation: J Perinatol. 2003 Jun;23(4):300-3
references.pmid: 12774137
references.citation: Pediatrics. 2007 Aug;120(2):e272-82
references.pmid: 17671038
references.citation: J Perinatol. 2012 Aug;32(8):608-13
references.pmid: 22076415
references.citation: Physiol Rev. 2010 Oct;90(4):1291-335
references.pmid: 20959617
references.citation: Am J Respir Crit Care Med. 2007 Nov 15;176(10):1035-40
references.pmid: 17702969
references.citation: Am J Physiol Lung Cell Mol Physiol. 2009 Sep;297(3):L506-11
references.pmid: 19617312